Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers

Programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) pathway blockade has become a promising therapeutic target in adult cancers. We evaluated PD‐L1 expression and tumor‐infiltrating CD8(+) T cells in formalin‐fixed, paraffin‐embedded tumor specimens from 53 untreated pediatric patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoki, Takahiro, Hino, Moeko, Koh, Katsuyoshi, Kyushiki, Masashi, Kishimoto, Hiroshi, Arakawa, Yuki, Hanada, Ryoji, Kawashima, Hiroshi, Kurihara, Jun, Shimojo, Naoki, Motohashi, Shinichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074238/
https://www.ncbi.nlm.nih.gov/pubmed/27135656
http://dx.doi.org/10.1002/pbc.26018
Descripción
Sumario:Programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) pathway blockade has become a promising therapeutic target in adult cancers. We evaluated PD‐L1 expression and tumor‐infiltrating CD8(+) T cells in formalin‐fixed, paraffin‐embedded tumor specimens from 53 untreated pediatric patients with eight cancer types: neuroblastoma, extracranial malignant germ cell tumor, hepatoblastoma, germinoma, medulloblastoma, renal tumor, rhabdomyosarcoma, and atypical teratoid/rhabdoid tumor. One rhabdomyosarcoma with the shortest survival exhibited membranous PD‐L1 expression and germinoma contained abundant tumor‐infiltrating CD8(+) T cells and PD‐L1‐positive macrophages. The PD‐1/PD‐L1 pathway tended to be inactive in pediatric cancers.

Ejemplares similares